Endologix Provides Update on Nellix PMA Process
Nellix is an investigational device in
company will discuss the updated Nellix PMA process as part of its business overview at its 2016 Investor Meeting, which is scheduled for
|Event:||Endologix Investor Meeting|
|Time:||4:30 to 7:00 pm ET (registration and refreshments begin at 4:30 pm ET; formal presentation begins at 5:00 pm ET)|
|811 7th Ave 53rd Street, New York, NY|
A live audio webcast of the investor meeting will be available by visiting the investor relations section of Endologix's website at www.endologix.com. Participants are encouraged to log on a few minutes prior to 5:00 pm ET in order to download any applicable audio software. A replay of the presentation will be available within 24 hours and will be available for approximately one year.
This communication includes statements that may be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including with respect to clinical outcomes and regulatory approval timelines, the accuracy of which are necessarily subject to risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Endologix. Many factors may cause actual results to differ materially from anticipated results, including unanticipated clinical outcomes and additional regulatory requirements. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Endologix undertakes no obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events. Please refer to Endologix's Annual Report on Form 10-K for the year ended December 31, 2015, and Endologix's subsequent filings with the Securities and Exchange Commission, for more detailed information regarding these risks and other factors that may cause actual results to differ materially from those expressed or implied.
Endologix, Inc. John McDermott, CEO Vaseem Mahboob, CFO (949) 595-7200 www.endologix.com INVESTOR CONTACTS: The Ruth Group Nick Laudico(646) 536-7030 Zack Kubow(646) 536-7020
News Provided by Acquire Media